Cargando…
Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
Despite significant advances in targeted therapies against the hyperactivated BRAF(V600)/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cells resistant to trametinib, an agent broadly use...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178474/ https://www.ncbi.nlm.nih.gov/pubmed/37175614 http://dx.doi.org/10.3390/ijms24097891 |